Speaker Profiles

Ylva Källman is an experienced moderator and communication professional with a strong background in learning conversations, public sector dialogues and public events.
She is known for her calm presence and engaging facilitation style she helps create thoughtful diskussions were both speakers and audiences feel involved.

Dr. Anurag K. Agrawal is a pediatric hematologist-oncologist and bone marrow transplantation physician. He joined the American Cancer Society in May 2024 and leads ACS’ global cancer support programs which focus on technical assistance to in-country partners, spanning 78 countries in the prior year. The work is cross continuum from cancer prevention/screening to patient support (patient education, patient navigation) and healthcare provider support/quality improvement initiatives.

Dr. Agrawal helped lead development of Southeast Asian Pediatric Hematology/Oncology (SEAPHO), which is focused on strategic initiatives to improve pediatric cancer outcomes in Vietnam including initiating a 2-year master’s level training program there since 2018 which now spans all regions of the country.

While full-time at UCSF Benioff Children’s Hospital from 2014-2024, he developed and directed the early phase and cellular therapies programs.

Prof. Elias Arnér is a Professor in Biochemistry at Karolinska Institutet, Stockholm, Sweden, and Head of the Department of Selenoprotein Research at the National Institute of Oncology, Budapest, Hungary.

He also serves as Director for CRKI, an umbrella organization for 400+ cancer reach PIs at Karolinska Institutet and Karolinska Comprehensive Cancer Center. His own research is on selenoproteins, redox signaling pathways, and anticancer therapies targeting selenoproteins.

Arnér is a Board member or in the Scientific Advisory Board of several academic bodies and biotech companies. He has published 185+ articles found in PubMed, cited 30,000+ times with an h-index of 78 (Google Scholar).

Roger Olofsson Bagge, MD, PhD is Professor of Cancer Surgery at the Sahlgrenska Academy, University of Gothenburg, and Senior Consultant Surgeon at Sahlgrenska University Hospital, Sweden.

He is a leading clinician-scientist in the melanoma field, with a particular focus on regional therapies, translational oncology, and integration of surgery with modern immunotherapy. He has authored over 200 peer-reviewed publications, and has contributed to high-impact journals including Nature, JCO, and Lancet Oncology.

He leads a multidisciplinary research group at the Sahlgrenska Center for Cancer Research and the Wallenberg Centre for Molecular and Translational Medicine. His work spans clinical trials, biomarker development, and novel treatment strategies for advanced melanoma.

LeeAnn Bailey is Branch Director of the Community Outreach Research and Engagement branch of the National Cancer Institute’s (NCI) Center to Reduce Cancer Health Disparities. In this role, she manages, develops, and assesses strategies for enhancing the integration and dissemination of community outreach and engagement efforts within and across NCI, as well as within the scientific and lay community through NCI-supported networks.

She also identifies and leverages opportunities to address unmet needs in cancer health disparities research. Recently, she has also become the lead of the early onset cancer initiative for the NCI. Prior to her tenure at NCI, she was a principal investigator researching tissue engineered products and cellular inflammatory responses at the National Institute of Standards and Technology as well as an adjunct professor at Morgan State University.

Dr. Bailey received her M.B.B.S (M.D. equivalent) from the University of Adelaide Medical School with an emphasis on aboriginal health and pediatric oncology. Dr. Bailey also has a Ph.D. in Biochemistry and Molecular Genetics and a M.S. in Biological and Physical Sciences from the University of Virginia School of Medicine.

Kara Bendle, Cleveland Clinic and Cleveland Clinic Children's, Co-administrative director of the Integrative Program for Young People withCancer.

Kara Bendle, MSN, RN, CPN, CNL is the Co-Administrative Director of the Integrative Program for Young People with Cancer and Program Manager for Fertility Preservation at Cleveland Clinic and Cleveland Clinic Children’s. In her role, she leads and supports cross-institutional program development focused on adolescents and young adults with cancer, with an emphasis on building integrated, system-wide pathways that connect patients to both clinical and psychosocial resources across the continuum of care.

Her work centers on proactive, patient-informed care delivery, ensuring that patient voices and lived experiences are embedded in program design, service development, and ongoing care models through active patient advisory engagement and collaboration with nonprofit and community partners.

Richard Rosenquist Brandell is a Professor and Senior Physician in Clinical Genetics at Karolinska Institutet and Karolinska University Hospital, Stockholm. He also serves as the Director of Genomic Medicine Sweden, a national infrastructure for implementation of genomic-based precision medicine.

He also serves as co-chair of the newly established Precision Omics Initiative Sweden (PROMISE). Richard Rosenquist Brandell is a member of the Nobel Assembly at Karolinska Institutet.

Jan Ellenberg, Director for SciLifeLab & Wallenberg National Program for Data-Driven Life Science

Jan Ellenberg is the director of SciLifeLab, the national research center for molecular biosciences, since 2024. He also holds a position as professor of cell biology and biophysics at Karolinska Institutet and as affiliated professor at Stockholm University and KTH. His research focuses on cell division and organization of the cell nucleus. He has recently received support from the Knut and Alice Wallenberg Foundation to launch a new strategic research program at SciLifeLab to create a virtual human cell, Alpha Cell, using imaging-based molecular mapping and AI.
Jan Ellenberg was previously at the European Molecular Biology Laboratory (EMBL) in Heidelberg, Germany, where he conducted groundbreaking research in cell biology. In addition to studying how cells divide, he has developed new approaches to systematically map molecular components in living cells over time. To this end, he advanced new methods in image analysis and modelling based on live-cell microscopy. The latter is a form of microscopy where biological processes in cells and tissues are studied studied directly in living systems. The research has provided new insights into fundamental molecular processes in living cells.

Professor Jonas Fuxe, MB and PhD from Karolinska Institutet, 2001, post doc at University of California, San Francisco, 2004-2007, Head of Department of Laboratory Medicine 2023. Research focus on Cancer Cell Plasticity and Metastasis.

Shridar Ganesan, MD, Ph.D, Director, Center for Molecular Oncology; Interim Deputy Director, NYU Perlmutter Cancer Center; Professor of Medicine, NYU Grossman School of Medicine.

Dr. Ganesan serves a Director of the Center for Molecular Oncology , Professor of Medicine at NYU Perlmutter Cancer Center, and Interim Deputy Director of the NYU Perlmutter Cancer Center. He is a medical oncologist and physician scientist with extensive experience in basic, translational, and clinical research, focused on DNA repair, breast cancer biology, and cancer genomics.

Dr. Ganesan received his MD and PhD in cell biology at Yale University before going on to postgraduate training in Internal Medicine at Brigham and Women’s Hospital where he served as chief resident, fellowship in Medical Oncology at the Dana-Farber Cancer Institute, followed by post-doctoral training in laboratory of Dr. David Livingston. He later held academic titles at several institutions, including Harvard Medical School and Rutgers Robert Wood Johnson Medical School.

Jonas Gårding, PhD, is Global Director of Partner Research at Elekta, where he leads
international collaborations with leading academic institutions and cancer centers to
advance innovation in radiotherapy.

He holds a PhD in computer science from KTH Royal Institute of Technology and has a background in engineering physics. Before joining Elekta, he was Assistant Professor at the Computational Vision and Active Perception (CVAP) Laboratory at KTH and a visiting research fellow at the University of Sheffield.

With more than three decades of experience across academia and industry, his work focuses on applying advanced computational methods to medical imaging, image-guided therapy, and the development of more effective, data-driven radiotherapy.

Margareta Haag, Chairperson of Nätverket mot cancer, the Swedish Network against Cancer – umbrella organisation for cancer profiled patient organizations since 2018. Patient advocate/representative Professional and patient experience Former Executive Director for an international professional federation, The Federation of Biomedical Laboratory Science, 1987 .

Lymphoedema patient since 1995 Competence, relevant assignments and activities Chair Nätverket mot cancer, Former Chair Svenska Ödemförbundet 2010-24 (now Honorary Chair), member of the steering group of All.Can.se, Member of the Steering Group of GMS (Genomic Medicine Sweden) and their Co-creation committee, member of the Person Council of the Centre for Patient Centered care, Gothenburg University, Personrådet inom GPCC (Centrum för personcentrerad vård, Göteborgs universitet).

Board member of the Agenda for Health and Prosperity 2021-25, Agenda för hälsa och välstånd, Research! Sweden member association Forska! Sveriges medlemsförening, member of the steering group for Vision Zero Cancer/ Test Bed Sweden Precision Health Cancer Council member, EUPATI Sweden and member of EUPATI.eu 2025 - Co-lead WG7 EU Project EU-CIP (Cancer Information Portal) 2025-29 Patients and citizens– together with Skåne CCC.

Member of OECI: Working Group for Patients – drafting recommendations for patient co-creation in EU CCC:s since 2025 Patient involvement and decsion charing Active in strategic discussions on patient co-creation together with patient advocates and researchers within GMS/KI, Biobank Sweden and ATMP Sweden. Member of the government reference groups for implementation of EU Beating Cancer Plan and digital infrastructure 2025 The National Board of Health and Welfare working groups: ECHoS 2024-25, EUnetCCC 2024 - , Patient Safety 2025 - Member of BBMRI-ERIC, CPE (Cancer Patients Europe), OECI Member of Advisory Boards of AMB@R, EU-project for digital rehabilitation in the Baltics and Skåne 2024 - Vinnova Project PROMISE - Precision Omics Initiative Sweden

Elham Hedayati, MD, PhD, Associate Professor of Oncology, Karolinska Institutet, Senior Consultant in Clinical Oncology, Södersjukhuset, Director of Research, Development, Education and Innovation (FoUUi), Södersjukhuset Co-founder, True Dose AB

Elham Hedayati, MD, PhD, is a senior oncologist, clinical researcher, and Associate Professor in Oncology at Karolinska Institutet and Södersjukhuset, Stockholm, where she also serves as Director of Research, Development, Education & Innovation (FoUUi).

Her work focuses on precision medicine, therapeutic drug monitoring (TDM), decentralized clinical trials, and implementation of innovative technologies in cancer care. She leads several national and international research initiatives aimed at improving individualized cancer treatment and translating research findings into clinical practice.

She is also co-founder and board member of True Dose AB, a spin-off from her research developed with support from KI Innovations and the Karolinska Institutet innovation ecosystem.

Madeleine Durbeej-Hjält, Professor and Secretary General, Swedish Research Council, obtained her PhD from Uppsala University, Sweden.

After a postdoctoral fellowship at the Howard Hughes Medical Institute, USA, she returned to Lund University, where she became a full professor in 2010. She served as vice head and head of the Department of Experimental Medical Science from 2012 to 2020.

She is currently Secretary General for Medicine and Health at the Swedish Research Council. Her main responsibilities include developing high-quality funding schemes and national research programmes. She also serves as Sweden’s national representative in several international organisations.

Michaela Hollis, State Secretary to Minister for Health Care Elisabet Lann, Ministry of Health and Social Affairs

Suzanne Håkansson - Senior Director Corporate Affairs, joined AstraZeneca in 2010 as Government Affairs Director with responsibility for public affairs. From 2014, Suzanne held the role of VP Healthcare Affairs with responsibility for subsidy and accessibility issues, health economics and external communications for the Nordic market company. In her current role, Suzanne is responsible for the AstraZeneca marketing company corporate affairs function and a member of the Sweden AB leadership team. She is also engaged in EU policy for several areas. She was one of the initiators of VisionZeroCancer in 2019 and engaged in the development of the initiative thereafter. Before Suzanne joined AstraZeneca, she held several roles in the public sector, including as Head of Global Analysis and Attaché Operations at the Institute for Growth Policy Studies, and as a Cabinet Counsellor at the Ministry of Enterprise, Innovation and Technology. She has also worked as a management consultant and as a business area manager for consulting operations in the area of growth analysis. Suzanne is a qualified business economist.

Andreas Hörnell, Chief of Staff, Precision Medicine Center Karolinska (PMCK)
Andreas has a background in management consulting and business development and has worked at Karolinska University Hospital since 2017.

He is working to drive the implementation of precision medicine into healthcare at PMCK. He holds an M.Sc. in Engineering Physics from the Royal Institute of Technology (KTH) in Stockholm and Ecole Centrale in Paris, and an Executive MBA from the Stockholm School of Economics.

Dr. Clifford Hudis, Chief Executive Officer/American Society of Clinical Oncology is the CEO of the American Society of Clinical Oncology (ASCO) and serves as executive vice chair of its Conquer Cancer Foundation.

He oversees a staff of about 500 who serve a global membership of over 50,000 investigators and clinicians as they seek to reduce the burden of cancer through research, education, and the delivery of the highest quality care possible.

ASCO holds the one of the world’s largest annual meetings focused on cancer research and care, publishes the high impact Journal of Clinical Oncology (and associated titles), supports and conducts research, defines optimal quality of care, and advocates for access for all. ASCO’s foundation, Conquer Cancer, funds more early-career physician scientists, without limits on geography or focus area, than any other independent cancer organization worldwide.

Martin Jansson is the Project Lead for establishing SweCan – Sweden’s Cancer Mission Hub – at the National Board of Health and Welfare. He has extensive experience in national coordination, policy development, and implementation within the health sector, with a particular focus on innovation, governance, and cross sector collaboration.

In SweCan, he is responsible for developing the structures, partnerships, and working methods that will strengthen Sweden’s capacity to advance and implement the cancer care of the future.

Ulrika Årehed Kågström, Secretary General, The Swedish Cancer Society, President, Union for International Cancer Control (UICC)

Ulrika Årehed Kågström is Secretary-General of the Swedish Cancer Society, President of UICC, board member of the Nordic Cancer Union and member of the Swedish Government’s Life Science Advisory Group.

Her background is in finance, crisis management and leading large and complex organisations in times of change. Ulrika is highly regarded for her extensive experience in strategic leadership and successful advocacy work. She is known to be a team player who listens and greatly values transparency.

Under Ulrika’s leadership, the Swedish Cancer Society has become the number 1 fundraising organisation in the country with a revenue that increased by more than 50 percent since Ulrika took office in 2016.

Prior to joining the Swedish Cancer Society in 2016, Ulrika was Secretary General of the Swedish Red Cross.

Anirban Maitra, M.B.B.S., Laura and Isaac Perlmutter Professor of Pathology, Director, Perlmutter Cancer Center.

Laura and Isaac Perlmutter Professor of Pathology, Director, Perlmutter Cancer Center
The overarching goal of the Maitra laboratory at Perlmutter Cancer Center is to improve the survival of patients with pancreatic cancer through earlier detection, cancer interception and rational therapies.

For nearly 25 years, our Laboratory has been singularly dedicated to the cause of researching pancreatic cancer, one of the most lethal cancers known to mankind, with a clear line of sight to translational advances that can improve patient outcomes in the clinic and favorably impact those at high risk of the disease.

Our research has been consistently supported by the National Cancer Institute (National Institutes of Health), as well as foundations such as Stand Up to Cancer (SU2C), Breakthrough Cancer, the Lustgarten Foundation for Pancreatic Cancer Research, and the Pancreatic Cancer Action Network.

Alex Millerna is Co-Director, NYU Langone’s Brain and Spine Tumor Center.

Eva Hernando Monge earned her PhD in Sciences (Molecular Biology) from the Universidad Autónoma de Madrid (Spain) in 1999. She completed postdoctoral training at Memorial Sloan Kettering Cancer Center in New York City and Cold Spring Harbor Laboratories. She joined the Department of Pathology at NYU School of Medicine in 2006 and is currently a tenured Professor.

She has served as vice chair of the Department of Pathology, associate director for basic science at the NCI-designated Perlmutter Cancer Center, and assistant dean for research integration. Her laboratory investigates the molecular basis of cancer metastasis, leveraging clinically relevant murine models and access to patient samples. She has published more than 100 peer-reviewed articles, including high-impact studies in Nature, Nature Medicine, Nature Cell Biology, Cancer Discovery, and Cancer Cell.

The Hernando lab discovered that melanoma’s metastatic potential often arises from the retention or reactivation of transcriptional programs characteristic of neural crest cells—the multipotent, highly migratory progenitors that give rise to melanocytes. Her research has identified novel drivers of melanoma maintenance and progression, including the stress-response factor HSF1 (Kourtis, Moubarak et al., Nat Cell Biol 2015), BET epigenetic readers (Fontanals-Cirera, Hasson et al., Mol Cell 2017), the histone demethylase PHF8 (Moubarak et al., Science Adv 2022), the orphan nuclear receptor NR2F2 (Davalos et al., Nat Comm 2023), and the homeodomain transcription factor HOXD13 (Berico et al., Cancer Discov 2026).

Additionally, her group identified non-coding RNAs that functionally contribute to various aspects of metastatic progression and therapeutic resistance, including microRNAs (Segura et al., PNAS 2009; Gaziel-Sovran et al., Cancer Cell 2011; Hanniford et al., JNCI 2015) and circular RNAs (Hanniford et al., Cancer Cell 202). The lab is also investigating the molecular basis of melanoma’s adaptation to the brain microenvironment. They have uncovered a novel connection between brain metastasis and neurodegenerative disorders, demonstrating a role for amyloid-beta in suppressing neuroinflammation during melanoma brain adaptation (Kleffman et al., Cancer Discov 2022).

Since its establishment, Dr. Hernando’s laboratory has been continuously funded by the National Cancer Institute (NCI/NIH), the Department of Defense (DOD), and prestigious foundations such as the American Cancer Society and the V Foundation.

Dr. Hernando has served as a permanent member of the Cancer Molecular Pathogenesis (CAMP) NIH Study Section and is currently a member of the programmatic review committee of the DOD Melanoma Research Program, as well as review panels for the Melanoma Research Foundation, the Melanoma Research Alliance, and the V Foundation.

In 2023, the Society of Melanoma Research awarded her the Estela Medrano Award for her important contributions to the field.

Mef Nilbert, MD, PhD, professor of Oncology, expert advisor cancer, National Board of Health & Welfare

Mef Nilbert is a medical oncologist with research focused at hereditary cancer, colorectal cancer and precision medicine. She acts as an adviser in cancer for the National Board of Health & Welfare, was responsible for drafting the updated Swedish Cancer Strategy and supports and coordinates Sweden’s engagement in the EU Beating Cancer Plan.

Birgitta Ohlsson, Former Minister for European Affairs; Patient Representative

Birgitta Ohlsson is a former Member of the Swedish Parliament and Sweden’s former Minister for European Union Affairs and Democracy. In recent years, she has been based in Washington, D.C., where she worked to advance global democracy at the National Democratic Institute.

In 2021, she was diagnosed with aggressive HER2-positive breast cancer in Sweden and received treatment at Karolinska University Hospital. In 2024, she was diagnosed with therapy-related acute leukemia in the United States and was treated at MedStar Georgetown University Hospital in Washington, D.C., where she also underwent a stem cell transplant.

She is currently running for election to the Swedish Parliament.

Jesse Rafel, Assistant Director & Vice Chair for Research, Institute for Innovations in Medical Education NYU Langone Health

Jesse Burk-Rafel, an assistant professor of medicine at NYU Grossman School of Medicine, directs research at the NYU Institute for Innovations in Medical Education. He is also a hospitalist and inaugural Research Coach in the Division of Hospital Medicine.

With a background in bioengineering and translational research, Jesse leads grant-funded studies exploring the intersection of medical education, informatics, and AI. His work aims to optimize trainee clinical performance and develop personalized educational interventions. Jesse lives with his wife and two children in the Lower East Side of New York City.

Dafna Bar-Sagi, PhD, Saul J. Farber Professor of Biochemistry and Molecular Pharmacology, Executive Vice President and Vice Dean for Science
Chief Scientific Officer

Dr. Bar-Sagi is a cancer biologist widely recognized for her work on pathophysiological processes that drive the initiation and progression of mutant Ras tumors. She has made fundamental contributions to the understanding of the mechanisms that couple extracellular signals to Ras activation of effector pathways that control cell proliferation and survival.

Dr. Bar-Sagi is also credited with the discovery of Ras oncogene-dependent mechanisms that enhance tumor cell fitness via immune evasion and metabolic adaptation. Her research contributions have been recognized by multiple awards. She is a Member of the American Academy of Arts and Sciences, a Member of the National Academy of Sciences, a Fellow of the American Association for Cancer Research, a Fellow of the National Academy of Inventors and the recipient of an NCI Outstanding Investigator Award (2016-2023), an AACR-WICR Memorial Award, and an NCI Merit Award.

Dr. Bar-Sagi is the Saul Farber Professor of Biochemistry and Molecular Pharmacology. Aside of leading her research program, Dr. Bar-Sagi is Executive Vice President and Vice Dean for Science, Chief Scientific Officer of NYU Langone Health. Prior to joining NYU Grossman School of Medicine in 2006 as chair of the Department of Biochemistry, Dr. Bar-Sagi headed the Department of Molecular Genetics and Microbiology at SUNY at Stony Brook.

Malin Sund, Professor of Surgery, University of Helsinki and Helsinki University Hospital, Finland, Umeå University, Sweden, Chair of the research board at the Swedish Cancer Society
Professor Malin Sund (University of Helsinki, Finland and Umeå University, Sweden) is an academic surgeon with a specific interest in surgical oncology.

She is the Chair of the Research Board at the Swedish Cancer Society. Her clinical subspeciality is breast and endocrine surgery. Her research focuses on breast and pancreatic cancer, with a specific focus on establishing clinically useful biomarkers that can aid in early detection, diagnostics, prognostication, and treatment prediction.

Carl Johan Sundberg (CJS), MD, PhD, Professor, Dean Karolinska Institutet Nord, is a licensed physician and professor at Karolinska Institutet where his research is focused on human genetics, genomics and epigenetics in relation to the health and functional benefits of exercise in elite athletes, in non-athlete populations and in patients (cardiovascular, psychiatry, oncology).

Another main research area concerns AI/ML-based computerized history taking, i.e. the patient interacts with a tablet or a computer and provides information about symptoms and other elements of history. CJS is dean KI North.

CJS received in 2022 H.M the King of Sweden’s medal for “significant contributions to research and science communication” and in 2005 the European Commission's Descartes Communication 50 000 € Prize for Excellence in Science Communication.

Professor  Matti Sällberg, DDS and PhD from Karolinska Institutet, 1992, post doc at The Scripps Research Institute, La Jolla, 1994-1996, professor in Biomedical Analysis at Karolinska Institutet since 2000, Head of Department of Laboratory Medicine 2011-2023,

Dean of KI Campus South 2024-2028. Research focus genetic vaccines and genetheraipes against viral infections and cancer.

Christine J. Toretti ,Ambassador of the United States of America to the Kingdom of Sweden, was nominated by President Trump to serve as the U.S. Ambassador to the Kingdom of Sweden in January 2025 and confirmed by the Senate in September 2025.

Ambassador Toretti is the former Chairman and CEO of S.W. Jack Drilling Company, then the largest land-based natural gas drilling company in the United States. She also served as the Chairman of S&T Bank, a publicly traded community bank based in Pennsylvania.

Her passions have focused on advancing women in all aspects of society. She has founded many efforts to support women in the corporate world, the political arena and in the arts.

Former leadership activities have included chair of The Andy Warhol Museum, trustee of The Carnegie, director of International Medical Corps and director the National Collegiate Athletic Association Leadership Advisory Board.
In appreciation of her efforts to advance women, she was presented with the Athena International Global Award of which only sixty have been awarded world-wide.

Erik Ullenhag is the Consul General of Sweden in New York since August 2024. He is a diplomat and lawyer by profession, with a background in politics as a Minister for Integration and Member of Parliament in Sweden. Prior to coming to New York, Erik was Sweden’s Ambassador to Israel from 2020 to 2024.

There he was instrumental in normalizing relations between Sweden and Israel, and hosted the first visit to Israel of a Swedish Foreign Minister in 10 years. Between 2016 and 2020, he was Sweden’s Ambassador to Jordan. His time there was focused on the bilateral relations with Jordan, and the response to the Syrian crises.

Theresa Vincent, PhD, Research Associate Professor, Department of Pathology, NYU Langone Health, Director, Organoid and Preclinical Assessment Platform, Perlmutter Cancer Center, NYU Langone Health, Scientific Director, Centre for Metastasis Research, Karolinska Institutet

Dr. Theresa Vincent is a cancer biologist who leads a transatlantic research group at NYU Langone Health and Karolinska Institutet, with research focused on tumor cell plasticity, metastasis, ribosome biology, and translational control. Her work investigates how specialized ribosome biogenesis fuel translational reprogramming in cancer cells, with the goal of identifying novel therapeutic vulnerabilities in metastatic disease.

Dr. Vincent leads the Organoid and Preclinical Assessment Platform at the Perlmutter Cancer Center, an integrated clinical-to-preclinical translational ecosystem utilizing patient-derived organoid models drawn from NYC’s uniquely diverse patient population to interrogate tumor heterogeneity, identify molecular drivers of disease progression, and evaluate therapeutic strategies to improve outcomes for all patients.

She serves as Scientific Director of the Centre for Metastasis Research at KI and is a founding member of the KI-NYULH Metastasis Alliance, a transatlantic initiative dedicated to understanding, predicting, and treating metastatic disease. Dr. Vincent also serves as Editor-in-Chief of Seminars in Cancer Biology.
Contact:
Theresa.Vincent@nyulangone.org | Theresa.Vincent@ki.se

Dr. Åsa Wallin is a Fund Manager at Almi Invest with a background in life science, deeptech, and innovation. With a PhD in Medicine and extensive experience across academia, industry, and venture capital, she focuses on supporting the commercialization and growth of research-driven companies.